Henan Implements New Pricing Standards for 49 Medical Services; Huaxi Tech Completes New Funding Round

1. National-level new raw material product falls in Qingpu

Recently, the 2025 Yangtze River Delta Integration Demonstration Zone Shanghai Qingpu Cosmetics Industry Innovation and Development Conference was held at the National Convention and Exhibition Center. With the core theme of "Promoting High-Quality Development of Qingpu's Cosmetics Industry," the conference established a collaborative platform for government, enterprises, and research institutions, comprehensively showcasing the innovative achievements and future prospects of high-quality development in the cosmetics industry within the Yangtze River Delta Integration Demonstration Zone in Shanghai’s Qingpu district. To further clarify industrial positioning and development pathways, the conference grandly released the "White Paper on the Cosmetics Industry in the Core Area of the Yangtze River Delta Integration Demonstration Zone - Qingpu." The white paper revealed that by leveraging the strategic advantages of the Yangtze River Delta Integration Demonstration Zone, China International Import Expo, and the Greater Hongqiao Business District, Qingpu has initially formed a full-chain closed-loop ecosystem encompassing "R&D - Production - Marketing - Logistics." (Eastday.com)

2. Henan Implements New Standards for 49 Medical Service Prices

Recently, it was learned from the Henan Provincial Medical Security Bureau that starting from October 20th, new standards will be implemented for 49 medical service price items including "outpatient consultation fee" and "B-ultrasound examination." This standardization and integration of medical service prices were determined based on relevant regulations from the National Healthcare Security Administration and combined with the actual situation in Henan Province. According to the mapping relationship before and after the standardization and integration, 180 existing price items such as "registration fee" and "ophthalmic A-scan" will be canceled. In accordance with the national project guidelines, the comprehensive outpatient and ultrasound examination medical service price items in Henan Province have been standardized and integrated into 49 unified national price projects. Government-guided prices for 43 price items, including "outpatient consultation fee (general outpatient)" and "A-mode ultrasound examination," have been established for provincially managed public medical institutions. (Zhengzhou Daily)

3. Fujian Province's "14th Five-Year Plan" Health Care Sector Reaches New Heights

Recently, the Press Office of the People's Government of Fujian Province held the tenth session of the series of themed press conferences on "High-Quality Completion of the '14th Five-Year Plan' and Striving for Excellence in the Construction of Chinese-Style Modernization." The event provided a comprehensive introduction to the achievements in the development of Fujian’s health care sector. Since the start of the "14th Five-Year Plan," the overall health level of residents in Fujian has significantly improved. Life expectancy at birth for the resident population has increased to 79.5 years, the maternal mortality rate has dropped to 7.14 per 100,000, and the infant mortality rate has decreased to 1.71‰. Major health indicators have consistently surpassed the national average, earning Fujian an "excellent" rating in the Healthy China Action assessment for two consecutive years. Over the past five years, Fujian’s medical and health service system has become more robust, with 30,500 medical and health institutions of various levels, 248,900 hospital beds, and 338,200 health technicians, providing solid health security for the province's 41.93 million people. (China Daily Network)

4. BrainCo Establishes New Company in Chengdu

Recently, BrainCo (Chengdu) Technology Co., Ltd. was established with a business scope including: sales of Class II medical devices; sales of artificial intelligence hardware; internet data services; development of artificial intelligence application software; and internet security services. Equity analysis shows that the company is wholly owned by BrainCo (Zhejiang). Founded in 2015, BrainCo is a pioneer and unicorn in China's brain-computer interface field. The company has successfully developed a mass-produced intuitively controlled smart bionic hand. BrainCo leads the industry in rehabilitation, health, and human-computer interaction, with over 420 authorized patents. It has made breakthroughs in the rehabilitation of people with disabilities and brain-related diseases, establishing itself as a leader in non-invasive brain-computer interface technology. Currently, BrainCo has launched multiple products such as smart bionic limbs and a brain-computer intelligent sleep device, indicating that brain-computer interface technology is gradually moving from laboratory research to commercial applications. (Red Star News)

5. Giant Medical is about to establish an IVD joint venture

Recently, Giant Medical Holdings plans to establish an IVD joint venture with Genetron Health in Singapore, with potential business expansion into Indonesia, Malaysia, and Singapore. The joint venture intends to register a new entity in Indonesia, focusing on the design, construction, and operation of clinical molecular diagnostic laboratories for precision oncology, and establishing in vitro diagnostic reagent production facilities when appropriate. The enterprise will offer advanced molecular diagnostic services, including early cancer screening (such as HCCscreen and HCCscan products based on NGS or qPCR technology), comprehensive genomic profiling, minimal residual disease monitoring, and non-invasive prenatal testing, among others. Initially, the focus will be on laboratory-developed tests, gradually expanding to local manufacturing and insurance coverage. The joint venture will collaborate with well-known hospitals and medical institutions in Indonesia, forming a joint board of directors and management team while handling regulatory procedures, with potential future expansion into the Southeast Asian market. (CACLP In Vitro Diagnostics Information)

6. Olympus Launches New Generation Bipolar High-Frequency Ultrasonic Scalpel

Recently, Olympus announced the launch of a new generation bipolar high-frequency ultrasonic scalpel --- Thunderbeat II. Designed specifically for laparoscopic and open surgeries, Thunderbeat II aims to achieve faster and more precise hemostasis, dissection, and large vessel transection. As the latest addition to the Thunderbeat series of innovative hybrid energy devices, Thunderbeat II not only inherits the advantages of its predecessor but also delivers dual improvements in the speed of hemostatic dissection and the safety of vascular closure. These performance enhancements are due to three key technological advantages that Olympus has incorporated into Thunderbeat II: three energy modes enabling versatile operation, meticulous design minimizing thermal damage, and an ergonomic handle with wireless sensing technology. (MedTF)

7. R&D Design Services Accelerate the Clinical Transformation of Medical Research Achievements

The R&D of medical devices is a complex and rigorous process involving multiple aspects such as technology, regulations, and clinical practices. Orthotec has a 20,000㎡ Science and Innovation Center and has established a Medical Device Research Institute dedicated to the clinical transformation of medical research achievements. It boasts a high-level, international, multidisciplinary professional team proficient in the entire process of R&D, regulations, clinical trials, registration, and production, capable of developing and producing various complex innovative products. With extensive project experience and industry resources, Orthotec has built a standardized, regulated, and digitalized full-process service system. It provides one-stop services from initial market research, product concept generation, product design and development to prototype production and testing. To date, Orthotec has had over 200 projects enter the review stage, more than 100 projects under development, with a 100% success rate in transformation. (Compiled by Orthotec)

8. Huaxi Technology Completes New Round of Financing

Recently, Hangzhou Huaxi Intelligent Technology Co., Ltd. announced the completion of its second angel round of financing in 2025. This round was led by Optics Valley Coffee Venture Capital, a leading institution in hard technology investment, with participation from investors in the elderly care industry. The funds will mainly be used to accelerate the mass production and market promotion of "HT-X2," the industry's first C-end embodied elderly care robot. Prior to this, Huaxi Technology's first product, HT-X1, had already been mass-produced and delivered in bulk to various elderly care scenarios, rapidly covering more than 8 provinces in China in a short period. Huaxi Technology was founded by Yan Chunqiu, the former product line and GTM director of Tmall Genie. The core team members come from well-known technology companies and research institutes such as Huawei, SenseTime, Alibaba, Dobot, Gaussian Robotics, CloudMinds, Tsinghua Holdings Boao, and others, covering key areas such as AI algorithms, hardware R&D, and the implementation of health care products. (Vcbeat)